TY - JOUR
T1 - Mapping the Patient-Oriented Prostate Utility Scale From the Expanded Prostate Cancer Index Composite and the Short-Form Health Surveys
AU - Zamora, Víctor
AU - Garin, Olatz
AU - Pardo, Yolanda
AU - Pont, Àngels
AU - Gutiérrez, Cristina
AU - Cabrera, Patricia
AU - Gómez-Veiga, Francisco
AU - Pijoan, José Ignacio
AU - Litwin, Mark S.
AU - Ferrer, Montse
AU - Ventura, Montse
AU - Guedea, Ferran
AU - Ferrer, Ferran
AU - Boladeras, Ana
AU - Slocker, Andrea
AU - Suárez, José Francisco
AU - Castells, Manuel
AU - Bonet, Xavier
AU - Delgado, David B.
AU - Ortiz, Ma José
AU - Herruzo, Ismael
AU - López-Torrecilla, José
AU - Pastor, Jorge
AU - Muñoz, Víctor
AU - Willsich, Patricia
AU - Vázquez, Marisa
AU - Roselló, Àlvar
AU - Eraso, Arantxa
AU - Ferrer, Carlos
AU - Sánchez, Ángel
AU - Macías, Víctor
AU - Fumadó, Lluís
AU - Jové, Josep
AU - Mira, Moisés
AU - Villafranca, Elena
AU - Morote, Juan
AU - Celma, Ana
AU - Samper, Pilar
AU - Glaría, Luís A.
AU - Cabeza, MaÁngeles
AU - Juan, Germán
AU - Méndez Ramírez, Samuel
AU - Palacios, Amalia
AU - Béjar, Amelia
AU - Garcia, Sonia
AU - Sabater, Sebastà
N1 - Publisher Copyright:
© 2021 ISPOR–The Professional Society for Health Economics and Outcomes Research
PY - 2021/11
Y1 - 2021/11
N2 - Objectives: This study aimed to develop mapping algorithms from the Expanded Prostate Cancer Index Composite (EPIC) and the Short-Form (SF) Health Surveys to the Patient-Oriented Prostate Utility Scale (PORPUS), an econometric instrument specifically developed for patients with prostate cancer. Methods: Data were drawn from 2 cohorts concurrently administering PORPUS, EPIC-50, and SF-36v2. The development cohort included patients who had received a diagnosis of localized or locally advanced prostate cancer from 2017 to 2019. The validation cohort included men who had received a diagnosis of localized prostate cancer from 2014 to 2016. Linear regression models were constructed with ln(1 − PORPUS utility) as the dependent variable and scores from the original and brief versions of the EPIC and SF as independent variables. The predictive capacity of mapping models constructed with all possible combinations of these 2 instruments was assessed through the proportion of variance explained (R2) and the agreement between predicted and observed values. Validation was based on the comparison between estimated and observed utility values in the validation cohort. Results: Models constructed with EPIC-50 with and without SF yielded the highest predictive capacity (R2 = 0.884, 0.871, and 0.842) in comparison with models constructed with EPIC-26 (R2 = 0.844, 0.827, and 0.776). The intraclass correlation coefficient was excellent in the 4 models (>0.9) with EPIC and SF. In the validation cohort, predicted PORPUS utilities were slightly higher than those observed, but differences were not statistically significant. Conclusions: Mapping algorithms from both the original and the abbreviated versions of the EPIC and the SF Health Surveys allow estimating PORPUS utilities for economic evaluations with cost-utility analyses in patients with prostate cancer.
AB - Objectives: This study aimed to develop mapping algorithms from the Expanded Prostate Cancer Index Composite (EPIC) and the Short-Form (SF) Health Surveys to the Patient-Oriented Prostate Utility Scale (PORPUS), an econometric instrument specifically developed for patients with prostate cancer. Methods: Data were drawn from 2 cohorts concurrently administering PORPUS, EPIC-50, and SF-36v2. The development cohort included patients who had received a diagnosis of localized or locally advanced prostate cancer from 2017 to 2019. The validation cohort included men who had received a diagnosis of localized prostate cancer from 2014 to 2016. Linear regression models were constructed with ln(1 − PORPUS utility) as the dependent variable and scores from the original and brief versions of the EPIC and SF as independent variables. The predictive capacity of mapping models constructed with all possible combinations of these 2 instruments was assessed through the proportion of variance explained (R2) and the agreement between predicted and observed values. Validation was based on the comparison between estimated and observed utility values in the validation cohort. Results: Models constructed with EPIC-50 with and without SF yielded the highest predictive capacity (R2 = 0.884, 0.871, and 0.842) in comparison with models constructed with EPIC-26 (R2 = 0.844, 0.827, and 0.776). The intraclass correlation coefficient was excellent in the 4 models (>0.9) with EPIC and SF. In the validation cohort, predicted PORPUS utilities were slightly higher than those observed, but differences were not statistically significant. Conclusions: Mapping algorithms from both the original and the abbreviated versions of the EPIC and the SF Health Surveys allow estimating PORPUS utilities for economic evaluations with cost-utility analyses in patients with prostate cancer.
KW - EPIC
KW - health utility measures
KW - localized prostate cancer
KW - mapping
KW - patient-reported outcomes
KW - PORPUS
UR - https://www.scopus.com/pages/publications/85114686913
U2 - 10.1016/j.jval.2021.03.021
DO - 10.1016/j.jval.2021.03.021
M3 - Article
C2 - 34711369
AN - SCOPUS:85114686913
SN - 1098-3015
VL - 24
SP - 1676
EP - 1685
JO - Value in health
JF - Value in health
IS - 11
ER -